Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
vchal         


MaxCyte (NASDAQ:MXCT) has signed a non-exclusive licensing deal with Vertex Pharmaceuticals (NASDAQ:VRTX) allowing the latter to use MaxCyte's (MXCT)Â Flow Electroporation technology and ExPERTâ¢ platform to develop gene-edited therapy exa-cel, previously known as CTX001.
Exact financial terms were not disclosed.
Exa-cel is an investigationalÂ ex vivoÂ CRISPR/Cas-9 gene-edited cell therapy under investigation for transfusion-dependent beta thalassemia or sickle cell disease.
MaxCyte's (MXCT) technology was also used in an agreement between the company and CRISPR Therapeutics (CRSP). Vertex is developing exa-cel, currently in phase 2/3, with CRISPR (CRSP).
Seeking Alpha's Quant Rating views MaxCyte as a hold with high marks for growth and momentum.